DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
QUICK SEARCH:   [advanced]


     

Drug Metabolism and Disposition Fast Forward
First published on July 30, 2007; DOI: 10.1124/dmd.107.017145

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.107.017145v1
35/11/2006    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sun, D.
Right arrow Articles by Lazarus, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sun, D.
Right arrow Articles by Lazarus, P.


Received for publication June 13, 2007.
Revised July 23, 2007.
Accepted for publication July 25, 2007.

Glucuronidation of active tamoxifen metabolites by the human UDP-glucuronosyltransferases (UGTs)

Dongxiao Sun 1, Arun K. Sharma 1, Ryan W. Dellinger 1, Andrea S. Blevins-Primeau 1, Renee Balliet 1, Gang Chen 2, Telih Boyiri 3, Shantu Amin 1, Philip Lazarus 4*

1 Department of Pharmacology, Penn State College of Medicine 2 Department of Health Eveluation Science, Penn State College of Medicine 3 Department of Biochemistry and Molecular Biology, Penn State College of Medicine 4 Penn State University College of Medicine

* Address correspondence to: E-mail: plazarus{at}psu.edu

Abstract

Tamoxifen (TAM) is an anti-estrogen that has been widely used in the treatment and prevention of breast cancer in women. One of the major mechanisms of metabolism and elimination of TAM and its major active metabolites, 4-hydroxy (OH)-TAM and 4-OH-N-desmethyl-TAM (endoxifen), is via glucuronidation. While limited studies have been performed characterizing the glucuronidation of 4-OH-TAM, no studies have been performed on endoxifen.In the present study, characterization of the glucuronidating activities of human UGTs against isomers of 4-OH-TAM and endoxifen was performed. Using homogenates of individual UGT-overexpressing cell lines, UGTs 2B7 {approx} 1A8 > UGT1A10 exhibited the highest overall O-glucuronidating activity against trans-4-OH-TAM as determined by Vmax/KM, with the hepatic enzyme, UGT2B7, exhibiting the highest binding affinity and lowest KM (3.7 µM). As determined by Vmax/KM, UGT1A10 exhibited the highest overall O-glucuronidating activity against cis-4-OH-TAM, 10-fold higher than the next-most active UGTs 1A1 and 2B7, but with UGT1A7 exhibiting the lowest KM. While both N- and O-glucuronidation occurred for 4-OH-TAM in human liver microsomes, only O-glucuronidating activity was observed for endoxifen; no endoxifen-N-glucuronidation was observed for any UGT tested. UGTs 1A10 {approx} 1A8 > 2B7 exhibited the highest overall glucuronidating activities as determined by Vmax/KM for trans-endoxifen, with the extra-hepatic enzyme, UGT1A10, exhibiting the highest binding affinity and lowest KM (39.9 µM). Similar to that observed for cis-4-OH-TAM, UGT1A10 also exhibited the highest activity for cis-endoxifen. These data suggest that several UGTs including UGTs 1A10, 2B7 and 1A8 play an important role in the metabolism of 4-OH-TAM and endoxifen.


Key words: anticancer agents, glucuronidation, HPLC, metabolite kinetics, phase II drug metabolism, UDP glucuronyltransferases


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
J. Tojcic, M.-O. Benoit-Biancamano, M. H. Court, R. J. Straka, P. Caron, and C. Guillemette
In Vitro Glucuronidation of Fenofibric Acid by Human UDP-Glucuronosyltransferases and Liver Microsomes
Drug Metab. Dispos., November 1, 2009; 37(11): 2236 - 2243.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
K. C. Olson, R. W. Dellinger, Q. Zhong, D. Sun, S. Amin, T. E. Spratt, and P. Lazarus
Functional Characterization of Low-Prevalence Missense Polymorphisms in the UDP-Glucuronosyltransferase 1A9 Gene
Drug Metab. Dispos., October 1, 2009; 37(10): 1999 - 2007.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
H. Brauch, T. E. Murdter, M. Eichelbaum, and M. Schwab
Pharmacogenomics of Tamoxifen Therapy
Clin. Chem., October 1, 2009; 55(10): 1770 - 1782.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. M. Balliet, G. Chen, C. J. Gallagher, R. W. Dellinger, D. Sun, and P. Lazarus
Characterization of UGTs Active against SAHA and Association between SAHA Glucuronidation Activity Phenotype with UGT Genotype
Cancer Res., April 1, 2009; 69(7): 2981 - 2989.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. S. Blevins-Primeau, D. Sun, G. Chen, A. K. Sharma, C. J. Gallagher, S. Amin, and P. Lazarus
Functional Significance of UDP-Glucuronosyltransferase Variants in the Metabolism of Active Tamoxifen Metabolites
Cancer Res., March 1, 2009; 69(5): 1892 - 1900.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
V. O. Dezentje, H.-J. Guchelaar, J. W.R. Nortier, C. J.H. van de Velde, and H. Gelderblom
Clinical Implications of CYP2D6 Genotyping in Tamoxifen Treatment for Breast Cancer
Clin. Cancer Res., January 1, 2009; 15(1): 15 - 21.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
P. J. Murphy
The Development of Drug Metabolism Research as Expressed in the Publications of ASPET: Part 3, 1984-2008
Drug Metab. Dispos., October 1, 2008; 36(10): 1977 - 1982.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.